iCardiac Launches Global Late Phase Respiratory and Cardiac Safety Study Spanning 28 Countries
Feb. 24, 2016, Rochester, NY - iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today announced it was awarded and is now enrolling patients in the largest late phase respiratory and cardiac safety study in the company’s history.
The three-year clinical trial will be conducted at sites across 28 countries and will include approximately 340,000 pulmonary function tests and 90,000 ECG reviews. iCardiac acquired the clinical trials division of nSpire Health in July 2015 and now offers both respiratory and cardiac safety assessment services to drug developers.
“iCardiac has the capacity and the expertise to support sponsors whether they are doing a small Phase II study with 10 sites or a large study with 750 sites,” said Brian Smith, Vice President of Project Operations, at iCardiac. “And whether a study is large or small, iCardiac continues to set itself apart based on our dedication to flexibility and study support, as well as the innovation embedded in our technology.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for cardiac safety and respiratory services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
